Vishal S. Parekh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Vishal S. Parekh has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Thompson
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA
1 shared publication - Biaoxin Chai
Division of Metabolism, Endocrinology and Diabetes and Department of Internal Medicine, and
1 shared publication - Emma C. Reck
Division of Metabolism, Endocrinology and Diabetes and Department of Internal Medicine, and
1 shared publication - Gemma L. Pearson
Division of Metabolism, Endocrinology & Diabetes and Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
1 shared publication - Jianhua Ren
Department of Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, USA
1 shared publication - Jie Zhu
Division of Metabolism, Endocrinology and Diabetes and Department of Internal Medicine, and
1 shared publication
Latest Publications
- Open Access
- 17 December 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (24)
Mitophagy protects β cells from inflammatory damage in diabetes
Inflammatory damage contributes to β cell failure in type 1 and 2 diabetes (T1D and T2D, respectively). Mitochondria are damaged by inflammatory signaling in β cells, resulting in impaired bioenergetics and initiation of proapoptotic machinery. Hence, the identification of protective responses to inflammation could lead to new therapeutic targets. Here, we report that mitophagy serves as a protective response to inflammatory stress in both human and rodent β cells. Utilizing in vivo mitophagy reporters, we observed that diabetogenic proinflammatory cytokines induced mitophagy in response to nitrosative/oxidative mitochondrial damage. Mitophagy-deficient β cells were sensitized to inflammatory stress, leading to the accumulation of fragmented dysfunctional mitochondria, increased β cell death, and hyperglycemia. Overexpression of CLEC16A, a T1D gene and mitophagy regulator whose expression in islets is protective against T1D, ameliorated cytokine-induced human β cell apoptosis. Thus, mitophagy promotes β cell survival and prevents diabetes by countering inflammatory injury. Targeting this pathway has the potential to prevent β cell failure in diabetes and may be beneficial in other inflammatory conditions.
- 17 December 2020
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 5 (24)
Open AccessMitophagy protects β cells from inflammatory damage in diabetes
Inflammatory damage contributes to β cell failure in type 1 and 2 diabetes (T1D and T2D, respectively). Mitochondria are damaged by inflammatory signaling in β cells, resulting in impaired bioenergetics and initiation of proapoptotic machinery. Hence, the identification of protective responses to inflammation could lead to new therapeutic targets. Here, we report that mitophagy serves as a protective response to inflammatory stress in both human and rodent β cells. Utilizing in vivo mitophagy reporters, we observed that diabetogenic proinflammatory cytokines induced mitophagy in response to nitrosative/oxidative mitochondrial damage. Mitophagy-deficient β cells were sensitized to inflammatory stress, leading to the accumulation of fragmented dysfunctional mitochondria, increased β cell death, and hyperglycemia. Overexpression of CLEC16A, a T1D gene and mitophagy regulator whose expression in islets is protective against T1D, ameliorated cytokine-induced human β cell apoptosis. Thus, mitophagy promotes β cell survival and prevents diabetes by countering inflammatory injury. Targeting this pathway has the potential to prevent β cell failure in diabetes and may be beneficial in other inflammatory conditions.